VistaGen Therapeutics, Inc is a biotechnology business based in the US. VistaGen Therapeutics shares (VTGN.US) are listed on the NASDAQ and all prices are listed in US Dollars. VistaGen Therapeutics employs 11 staff and has a trailing 12-month revenue of around $647,600.
How to buy shares in VistaGen Therapeutics
- Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
- Open your account. You'll need your ID, bank details and national insurance number.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: VTGN in this case.
- Research VistaGen Therapeutics shares. The platform should provide the latest information available.
- Buy your VistaGen Therapeutics shares. It's that simple.
What's in this guide?
- Can I buy shares in VistaGen Therapeutics?
- VistaGen Therapeutics shares summary
- Compare share dealing platforms
- Is VistaGen Therapeutics stock a buy or sell?
- Can I short VistaGen Therapeutics shares?
- VistaGen Therapeutics's financials
- How volatile are VistaGen Therapeutics shares?
- Does VistaGen Therapeutics pay a dividend?
- Have VistaGen Therapeutics shares ever split?
- Other common questions
VistaGen Therapeutics share priceUse our graph to track the performance of VTGN stocks over time.
VistaGen Therapeutics shares at a glance
|Latest market close||$N/A|
|52-week range||$0.35 - $3.18|
|50-day moving average||$2.212|
|200-day moving average||$1.5481|
|Wall St. target price||$5.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.829|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy VistaGen Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
VistaGen Therapeutics financials
|Gross profit TTM||USD$0|
|Return on assets TTM||-16.34%|
|Return on equity TTM||-30.49%|
|Market capitalisation||USD$293.2 million|
TTM: trailing 12 months
How to short and sell VistaGen Therapeutics shares
- Create a CFD or spread betting account.
- Search for the stock code. E.g. "VTGN.US"
- Choose your position size.
- Select "sell" rather than "buy".
- Confirm your position and keep tabs on it. You may wish to set limits on your position.
There are currently 6.2 million VistaGen Therapeutics shares held short by investors – that's known as VistaGen Therapeutics's "short interest". This figure is 32.5% down from 9.2 million last month.
There are a few different ways that this level of interest in shorting VistaGen Therapeutics shares can be evaluated.
VistaGen Therapeutics's "short interest ratio" (SIR)
VistaGen Therapeutics's "short interest ratio" (SIR) is the quantity of VistaGen Therapeutics shares currently shorted divided by the average quantity of VistaGen Therapeutics shares traded daily (recently around 1.9 million). VistaGen Therapeutics's SIR currently stands at 3.21. In other words for every 100,000 VistaGen Therapeutics shares traded daily on the market, roughly 3210 shares are currently held short.
However VistaGen Therapeutics's short interest can also be evaluated against the total number of VistaGen Therapeutics shares, or, against the total number of tradable VistaGen Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case VistaGen Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 VistaGen Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0434% of the tradable shares (for every 100,000 tradable VistaGen Therapeutics shares, roughly 43 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against VistaGen Therapeutics.
Find out more about how you can short VistaGen Therapeutics stock.
VistaGen Therapeutics share dividends
We're not expecting VistaGen Therapeutics to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Have VistaGen Therapeutics's shares ever split?
VistaGen Therapeutics's shares were split on a 1:20 basis on 13 August 2014. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your VistaGen Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for VistaGen Therapeutics shares which in turn could have impacted VistaGen Therapeutics's share price.
VistaGen Therapeutics share price volatility
Over the last 12 months, VistaGen Therapeutics's shares have ranged in value from as little as $0.35 up to $3.18. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while VistaGen Therapeutics's is 0.8174. This would suggest that VistaGen Therapeutics's shares are less volatile than average (for this exchange).
VistaGen Therapeutics overview
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license and option agreements with Pherin Pharmaceuticals, Inc.; license and collaboration agreement with EverInsight Therapeutics Inc.; and license and sublicense agreement with BlueRock Therapeutics, LP. The company was founded in 1998 and is headquartered in South San Francisco, California.
Frequently asked questions
More on investing
Companies are going public via direct listings and IPOs. Which should you invest in?Read more…
Biden’s plan to replace the federal fleet with American-made electric vehicles gives another boost to a red-hot sector led by Tesla.Read more…
Cruise ship stocks are sailing through murky waters, but can they rise?Read more…
More guides on Finder
How to buy Sanofi stock in Canada | $45.8
Steps to owning and managing SNY, with 24-hour and historical pricing before you buy.
How to buy NorthWestern Corporation stock in Canada
Steps to owning and managing NorthWestern Corporation stocks, with 24-hour and historical pricing before you buy.
How to buy Noble Corporation stock in Canada
Steps to owning and managing Noble Corporation stocks, with 24-hour and historical pricing before you buy.
How to buy NMI stock in Canada
Steps to owning and managing NMI stocks, with 24-hour and historical pricing before you buy.
How to buy nLIGHT stock in Canada
Steps to owning and managing nLIGHT stocks, with 24-hour and historical pricing before you buy.
How to buy NIO stock in Canada | $46.81
Steps to owning and managing NIO stocks, with 24-hour and historical pricing before you buy.
How to buy Nielsen stock in Canada
Steps to owning and managing Nielsen stocks, with 24-hour and historical pricing before you buy.
How to buy Newtek Business Services stock in Canada
Steps to owning and managing Newtek Business Services stocks, with 24-hour and historical pricing before you buy.
How to buy New Fortress Energy stock in Canada
Steps to owning and managing New Fortress Energy stocks, with 24-hour and historical pricing before you buy.
How to buy NeoGenomics stock in Canada
Steps to owning and managing NeoGenomics stocks, with 24-hour and historical pricing before you buy.